Cognition Therapeutics股價在DLB研究結果公布後飆升

英為財情

2025/07/16

Investing.com -- Cognition Therapeutics Inc (NASDAQ:CGTX)股價上漲14%，此前該公司宣佈將展示其用於治療路易體癡呆症(DLB)的二期研究結果。這家臨床階段神經退行性疾病公司透露，James E. Galvin博士將於2025年7月29日在阿爾茨海默病協會國際會議上展示zervimesine (CT1812)二期"SHIMMER"研究的...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2551269891"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551269891\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551269891?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-16 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551269891","market":"hk","top_or_hot":-1,"title":"Cognition Therapeutics股價在DLB研究結果公布後飆升","media":"英為財情","content":"<div>\n<p>Investing.com --  Cognition Therapeutics  Inc (NASDAQ:CGTX)股價上漲14%，此前該公司宣佈將展示其用於治療路易體癡呆症(DLB)的二期研究結果。\n這家臨床階段神經退行性疾病公司透露，James E. Galvin博士將於2025年7月29日在阿爾茨海默病協會國際會議上展示zervimesine (CT1812)二期\"SHIMMER\"研究的...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2888586\">網頁鏈接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cognition Therapeutics股價在DLB研究結果公布後飆升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCognition Therapeutics股價在DLB研究結果公布後飆升\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">英為財情</strong><span class=\"h-time small\">2025-07-16 21:51</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Investing.com --  Cognition Therapeutics  Inc (NASDAQ:CGTX)股價上漲14%，此前該公司宣佈將展示其用於治療路易體癡呆症(DLB)的二期研究結果。\n這家臨床階段神經退行性疾病公司透露，James E. Galvin博士將於2025年7月29日在阿爾茨海默病協會國際會議上展示zervimesine (CT1812)二期\"SHIMMER\"研究的...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2888586\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2888586\">英為財情</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0240877869.USD","symbol_name":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2888586","article_id":"2551269891","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2888586","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2551269891","pubTimestamp":1752673860,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com --  Cognition Therapeutics  Inc 股價上漲14%，此前該公司宣佈將展示其用於治療路易體痴呆症的二期研究結果。據該公司介紹，SHIMMER研究表明，zervimesine治療減緩了DLB症狀的進展，對神經精神、運動、功能和認知方面產生了顯著影響。Galvin博士表示：\"二期SHIMMER研究的結果為數百萬DLB患者及其醫療團隊帶來了希望，他們一直在努力治療這種複雜疾病。目前，尚無獲批用於DLB的疾病修飾性治療藥物。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","CGTX":"Cognition Therapeutics, Inc","BK4007":"制药","LENZ":"Therapeutics","DLB":"杜比","BK4097":"系统软件","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","BK4539":"次新股","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","BK4139":"生物科技","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC"},"translate_title":"Cognition Therapeutics Stock Soars After DLB Study Results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"DLB":1,"CGTX":1},"content_text":"Investing.com --  Cognition Therapeutics  Inc (NASDAQ:CGTX)股價上漲14%，此前該公司宣佈將展示其用於治療路易體痴呆症(DLB)的二期研究結果。\n這家臨床階段神經退行性疾病公司透露，James E. Galvin博士將於2025年7月29日在阿爾茨海默病協會國際會議上展示zervimesine (CT1812)二期\"SHIMMER\"研究的發現。指導該研究的Galvin博士隸屬於邁阿密大學米勒醫學院。\n據該公司介紹，SHIMMER研究表明，zervimesine治療減緩了DLB症狀的進展，對神經精神、運動、功能和認知方面產生了顯著影響。該藥物正在開發為DLB的每日一次口服藥物，DLB影響約140萬美國人，是第二常見的痴呆症原因。\nGalvin博士表示：\"二期SHIMMER研究的結果為數百萬DLB患者及其醫療團隊帶來了希望，他們一直在努力治療這種複雜疾病。我和同事們認為，一種每日一次的口服藥物具有巨大潛力，它可以減緩疾病進展，同時減輕DLB一些最麻煩症狀的嚴重程度和頻率。\"\n該公司還計劃在同一會議上展示其針對阿爾茨海默病患者的二期\"SHINE\"研究結果。該研究顯示，與安慰劑相比，zervimesine更好地保留了認知和功能能力，在p-Tau217生物標誌物水平較低的患者中效果尤為顯著。\n目前，尚無獲批用於DLB的疾病修飾性治療藥物。DLB通常表現為幻覺、認知障礙、運動障礙、睡眠障礙和注意力波動。\n\n本文由人工智能協助翻譯。更多信息，請參見我們的使用條款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}